Home / Costs / Medicaid by state
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Disclosure: we may earn a commission if you use certain links on this page. Compensation does not change our published methodology, scoring, or editorial conclusions.
Written by Kim Callender, NP, FNP-BC·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Prices verified July 12, 2026·Methodology v1.0

Medicaid GLP-1 coverage by state: the 2026 tracker

Direct answer

What we evaluated: state Medicaid coverage of GLP-1 medications for obesity, against the primary tracker (KFF) and dated state bulletins
Date verified: January 2026 (KFF); state actions through April 2026
Direct answer: 13 state Medicaid fee-for-service programmes cover GLP-1s for obesity as of January 2026 — down from 16 after California, New Hampshire, Pennsylvania and South Carolina all eliminated coverage on January 1, 2026. Massachusetts is scheduled to end coverage on July 1, 2026. North Carolina reinstated coverage in December 2025 and Tennessee reversed its exclusion in August 2025
Necessary qualification: you will see other sites claim 36 or 38 states. Those counts include managed-care plans, diabetes-only coverage, or 'Saxenda only' treated as equivalent to full coverage. Even where obesity coverage is excluded, four federal rules still give you a path — read those first
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.

Every dated state action we can source

These are the only state Medicaid changes for which we hold a dated, citable bulletin. Four states cut coverage on a single day — 1 January 2026 — taking the national total from 16 to 13. We do not fill in the other states with a guess.

Dated state Medicaid actions on GLP-1 obesity coverage
StateEffectiveWhat happenedSource
TennesseeAugust 1, 2025TennCare reversed its long-standing exclusion on August 1, 2025TennCare pharmacy bulletin
North CarolinaDecember 12, 2025North Carolina REINSTATED coverage on December 12, 2025NC Medicaid PDL, January 2026
CaliforniaJanuary 1, 2026Medi-Cal ELIMINATED weight-loss GLP-1 coverage on January 1, 2026Medi-Cal Rx Contract Drugs List; KFF, January 2026
PennsylvaniaJanuary 1, 2026Pennsylvania eliminated adult obesity GLP-1 coverage on January 1, 2026PA DHS; KFF, January 2026
New HampshireJanuary 1, 2026New Hampshire eliminated obesity GLP-1 coverage on January 1, 2026KFF, January 2026
South CarolinaJanuary 1, 2026South Carolina eliminated obesity GLP-1 coverage on January 1, 2026KFF, January 2026
MichiganJanuary 2026Michigan sharply restricted coverage in January 2026MDHHS provider notification L 25-73
MassachusettsMarch 12, 2026MassHealth is scheduled to END weight-loss GLP-1 coverage on July 1, 2026MassHealth Pharmacy Facts 271, March 12, 2026

Four federal rules that apply in every state

These are the most useful facts on this page, and they are true regardless of what your state decided. If your state has excluded obesity coverage, read these before concluding you have no path.

Type 2 diabetes is always covered — in every state
Every state Medicaid programme is federally required to cover GLP-1s prescribed for type 2 diabetes. A state that excluded obesity coverage did not exclude diabetes coverage. If you have a documented type 2 diabetes diagnosis, the exclusion you have read about probably does not apply to you.
Under-21 is federally protected — even where adults are excluded
Federal EPSDT law requires Medicaid to cover medically necessary treatment for enrollees under 21, even where that treatment is excluded for adults. A plan cannot apply a blanket 'we don't cover weight-loss drugs' exclusion to someone under 21. Pennsylvania's January 2026 cut explicitly preserved under-21 access for exactly this reason. Almost no comparison page mentions this, and for a parent it is the single most useful fact on the page.
Other approved indications survive an obesity exclusion
Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024). Wegovy is approved for cardiovascular risk reduction (March 2024) and for noncirrhotic MASH (August 2025). These are separate indications with separate diagnosis codes. California's Medi-Cal explicitly confirmed Wegovy for MASH remains covered even after its obesity cut.
Prior authorisation is universal
Every state that covers GLP-1s for obesity requires prior authorisation — typically BMI 30+, or 27+ with a weight-related comorbidity, and often documentation of a prior lifestyle attempt.

Why published 50-state tables contradict each other

13 or 36 or 38? They cannot all be rightBe sceptical of any 50-state Medicaid table — including the reasoning behind ours. Researching this, we found published sources claiming 13, 36 and 38 states cover GLP-1s for obesity, for the same period. They cannot all be right.

The discrepancy comes from counting different things: fee-for-service programmes versus managed-care plans; diabetes coverage versus obesity coverage; and 'covers Saxenda only, with BMI 35+ and multiple comorbidities' being counted identically to 'covers Wegovy and Zepbound'.

We follow KFF, the primary tracker, which counts fee-for-service obesity coverage: 13 states as of January 2026 — down from 16 after California, New Hampshire, Pennsylvania and South Carolina all cut coverage on January 1. Where we hold a dated state bulletin we cite it. Where we do not, we say so rather than filling the cell with a guess.

If you have no coverage: what cash actually costs now

The cheapest FDA-approved option is $149The cheapest FDA-approved GLP-1 for weight loss is now oral, and it undercuts most of the compounded market. Foundayo (orforglipron) starts at $149/month at the 0.8mg dose through LillyDirect. The oral Wegovy tablet is $149/month through NovoCare at 1.5mg and 4mg.

An FDA-approved, quality-verified, manufacturer-supplied medication at $149, against a compounded market that mostly runs $169-$399. The catch is dose escalation — Foundayo rises to $199, then $299, then $349 as you titrate, and at the top doses it has its own 45-day refill rule (it drops back to $299 if you refill in time). But for a starting patient, or anyone maintaining on a lower dose, the brand oral pill is now among the cheapest legitimate options in the entire category — and almost no comparison site has caught up.

The assumption that losing Medicaid coverage means paying $1,300 a month is out of date. Brand Zepbound is $299–$449 through LillyDirect. Brand Wegovy is $349 through NovoCare, and the oral Wegovy tablet is $149. Foundayo, Lilly's FDA-approved oral GLP-1, starts at $149. See the full pricing database.

All 50 states

Alabama

Alaska

Arizona

Arkansas

California

Colorado

Connecticut

Delaware

District of Columbia

Florida

Georgia

Hawaii

Idaho

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maine

Maryland

Massachusetts

Michigan

Minnesota

Mississippi

Missouri

Montana

Nebraska

Nevada

New Hampshire

New Jersey

New Mexico

New York

North Carolina

North Dakota

Ohio

Oklahoma

Oregon

Pennsylvania

Rhode Island

South Carolina

South Dakota

Tennessee

Texas

Utah

Vermont

Virginia

Washington

West Virginia

Wisconsin

Wyoming

Frequently asked questions

How many states cover GLP-1s for weight loss under Medicaid?

13, as of January 2026, per KFF — down from 16 after California, New Hampshire, Pennsylvania and South Carolina all eliminated coverage on January 1. You will see other numbers (36, 38) on other sites; those count managed-care plans, diabetes coverage, or 'Saxenda only' the same as full coverage.

My state doesn't cover it. Do I really have no options?

Probably not. Four federal rules still apply. Type 2 diabetes coverage is federally required everywhere. If you are under 21, EPSDT law protects you even where adults are excluded. Zepbound is separately approved for sleep apnea, and Wegovy for cardiovascular risk and MASH — different diagnosis codes that survive an obesity cut. And cash-pay is now far cheaper than most people think: the FDA-approved Foundayo oral pill is $149/month.

Which states changed most recently?

Massachusetts is scheduled to END weight-loss coverage on July 1, 2026 — if you are covered there, verify your renewal timeline. California, New Hampshire, Pennsylvania and South Carolina all cut on January 1, 2026. Michigan sharply restricted. North Carolina reinstated on December 12, 2025, and Tennessee reversed its exclusion in August 2025.

Why do 50-state Medicaid tables disagree with each other?

Because they count different things — fee-for-service versus managed care, obesity versus diabetes, and 'covers Saxenda with BMI 35+ and multiple comorbidities' counted identically to 'covers Wegovy and Zepbound'. We follow KFF and cite dated state bulletins, and where we have neither we say so.

Sources

  1. KFF — "Medicaid Coverage of and Spending on GLP-1s", January 2026. The primary tracker; the source of the 13-state count.
  2. Medi-Cal Rx Contract Drugs List — California, effective January 1, 2026.
  3. MDHHS provider notification L 25-73 — Michigan restriction.
  4. MassHealth Pharmacy Facts 271, March 12, 2026 — scheduled July 1, 2026 change.
  5. NC Medicaid Preferred Drug List, January 2026 — reinstatement of GLP-1 weight-management class.
  6. TennCare pharmacy bulletin — August 1, 2025 coverage expansion.
  7. Federal EPSDT requirements; FDA approvals for Zepbound (OSA, December 2024) and Wegovy (CV risk, March 2024; MASH, August 2025).
  8. Our source hierarchy. We do not treat an affiliate comparison site as evidence.

Spotted an error? Submit a correction.